versão On-line ISSN 2078-5135
versão impressa ISSN 0256-9574
SAMJ, S. Afr. med. j. vol.101 no.10 Cape Town Out. 2011
ISSUES IN MEDICINE
HIV prevention and treatment for South African men who have sex with men
Kevin B Rebe; Helen Struthers; Glenn de Swardt; James A McIntyre
Men who have sex with men (MSM) are at high risk for HIV acquisition and transmission owing to the high risks associated with unprotected anal sex and barriers to accessing appropriate health services. Globally HIV prevention is failing among MSM, as evidenced by high seroconversion rates. Prevention interventions for MSM are more limited than for heterosexual individuals. Prevention programmes should embrace early initiation of antiretroviral therapy for positive clients as part oftheir programming. High transmission risk groups such as MSMwill benefit from such interventions.
Initiating antiretroviral therapy (ART) at a CD4 cell count of <350 cells/µl has better outcomes than postponing treatment until more immune system damage has occurred,1 an opinion endorsed in expert guidelines from the World Health Organization, US Public Health and other academic institutions.2,3 Some experts have motivated for even earlier ART initiation (CD4 count <500 cells/µl) to improve patient outcomes and to lower viral loads in communities to decrease HIV transmission events, a strategy known as 'treatment as prevention'.4 Better ART drugs and a rapid drug-development pipeline favour earlier introduction of treatment. Until recently, the South African ART guidelines diverged from world opinion in delaying initiation in HIV-positive adults who are not pregnant or tuberculosis (TB) co-infected until a CD4 count of 200 cells/µl was reached.5 The South African Government (SAG) has recently announced that it will raise the CD4 threshold to 350 cells/ µl for all HIV-positive clients accessing state facilities for sponsored ART. This should be applauded and will provide an opportunity to lower transmission rates at community level, especially in groups who have the highest risk for HIV transmission, including men who have sex with men (MSM), commercial sex workers (CSWs), substance abusers, particularly intravenous drug users (IDUs), and serodiscordant couples.
Modelling studies demonstrate that targeted programmes addressing HIV among MSM positively impact on overall HIV rates in countries with generalised epidemics.6 The Soweto Men's Study showed that 50% of African MSM participants also had sex with women, and high rates of HIV among MSM could be driving HIV incidence in South African women.7 All South Africans might therefore benefit from an immediate move to initiate MSM on ART at a CD4 count of 350 cells/µl.
HIV transmission is dependent on the route of acquisition, the infecting viral load and the presence of inflammation and activated immune system cells below mucosal surfaces.8 Addressing these factors lowers HIV transmissibility. Unprotected, especially receptive, anal sex remains a high-risk behaviour for HIV transmission with a transmission risk about 18 times higher than for penile-vaginal sex, and is a major driver of high HIV rates among MSM.9
IDUs who inject themselves with HIV-contaminated needles provide a direct access point for HIV, and established infection can therefore occur with relatively lower viral loads. CSWs are likely to transmit HIV if they become infected themselves because of the greater number of sex partners that they encounter. All these population groups benefit from targeted HIV programmes.
Addressing HIV among MSM
The odds ratio for African MSM testing HIV positive is 3.8 compared with their heterosexual male counterparts.10 Data confirm that African MSM are a particularly vulnerable group, and a high HIV prevalence has been recorded in South Africa with rates ranging between 10.4% and 33.9%.7,11 Reasons include the psychological impact of living in a heteronormative, stigmatising society, perceived barriers to health care, and sexual behaviours that facilitate transmission of HIV.
Prevention of HIV transmission among MSM is failing worldwide with ongoing high seroconversion rates.12,13 MSM suffer from stigma and discrimination, which is often systematised and sanctioned by country leaders. The overwhelming prevalence of HIV among heterosexual individuals has resulted in messaging that is heteronormative and has failed to address the risks associated with unprotected anal sex.
HIV risk reduction tools for MSM are limited or are ineffective.12 Condoms are effective, but use remains inconsistent. Latexcompatible lubricants are required for anal sex with a condom, but are expensive and not widely available in Africa. Treatment of sexually transmitted infections (STIs) which cause mucosal disruption lowers HIV acquisition risk; however, STI incidence is increasing among MSM even in developed countries with good messaging and excellent health care infrastructures.14,15
Post-exposure prophylaxis (PEP) ART for MSM who may have been exposed to HIV is likely to be protective, although many structural barriers to access still exist. Proof of concept of the efficacy of pre-exposure prophylaxis (PrEP) comes from the iPrEx study in which long-term use of tenofovir and emtricitabine (Truvada) was associated with a 40% lower risk of seroconversion among MSM.16 Many issues relating to the implementation of PrEP remain, including concerns of increasing risky behaviours. PrEP remains unavailable to most African MSM.
Vaginal use of tenofovir-based gel can reduce a woman's chance of becoming HIV infected by 39%;17 similar results have not been established for rectal microbicides, and more development work is needed to make this intervention applicable for MSM.
Male circumcision (MC) has become an important prevention tool for heterosexual men,18 but cannot protect men who acquire HIV infection anally. MC may provide some protection for MSM who practise exclusively penetrative anal sex.19-21 High levels of bisexual concurrency have been noted among some African MSM, who might benefit from MC to reduce their risk of vaginal acquisition of HIV.19 There are no current recommendations to offer MC to MSM as a risk reduction strategy.
Preliminary reports from the HPTN 052 study showed that early ART initiation among HIV-discordant couples was associated with a 96% reduction in HIV seroconversion.22 Although the participants in this study were predominantly heterosexual couples, it is plausible that this benefit will hold true for MSM. Considering the poor efficacy or availability of HIV risk-reduction interventions for MSM, early treatment with ART to lower viral load and thus infectivity of MSM is an immediately available and implementable intervention.4
State-supported MSM-targeted health services already exist in South Africa, namely the Ivan Toms (Cape Town) and Simon Nkoli (Soweto) Centres for Men's Health, which are able to attract African MSM into sexual health and HIV care. These clinics previously missed the opportunity to initiate their clients on early treatment to improve individual outcomes and, importantly, begin to address high HIV transmission rates among these men. The revised SAG guidelines will allow these concerns to be addressed.
The positive benefits of early ART initiation for HIV-positive MSM are clear. This strategy conforms to evidence-based ART initiation guidelines, which ideally should be implemented for the population at large when funding and resources allow, but urgently for MSM and other high-risk communities.
Acknowledgements. K Rebe conceived the idea and undertook the literature search; J McIntyre, H Struthers and G de Swardt contributed additional ideas and contributed to the manuscript.
1. Stern J, Costagliola D, De Wolf F, Phillips A, Harris R, Funk M. Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies. Lancet 2009;18(373):1314-1316. [ Links ]
2. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. Aids Info 2009; 1 December: 1-161. [ Links ]
4. Hirschel B. Anti-HIV drugs for prevention. Presented at the 18th International AIDS Conference, Vienna, 18-23 July 2010. [ Links ]
6. Baral SD. Know your epidemic and knowing your response. MSM and their needs in low-and middleincome countries. Presented at the 18th International AIDS Conference, Vienna, 18-23 July 2010. [ Links ]
7. Lane T, Raymond F, Dladla S, et al. High HIV prevalence among men who have sex with men in Soweto, South Africa: Results from the Soweto Men's Study. AIDS Behav 2009;15(3):626-634. [ Links ]
8. Fauci A. New concepts in HIV/AIDS pathogenesis: Implications for Interventions. Presented at the 18th International AIDS Conference, Vienna. 18-23 July 2010. [ Links ]
9. Baggaley R, White R, Boily M. HIV transmission risk through anal intercourse, systematic review, meta-analysis and implications for HIV prevention. Int J Epidemiol 2010;39(4):1048-1063. [ Links ]
10. Baral SD. Elevated risk for HIV infection among men who have sex with men in low- and middleincome countries 2000-2006. PLoS Med 2007;4(12):1901-1911. [ Links ]
11. Burrell E, Mark D, Grant R, Wood R, Bekker LG. Sexual risk behaviours and HIV-1 prevalence among urban men who have sex with men in Cape Town, South Africa. Journal of Sexual Health 2010;7(2):149-153. [ Links ]
12. Beyrer C. Global prevention of HIV infection for neglected populations: men who have sex with men. Clin Infect Dis 2010;15(50):S108-113. [ Links ]
13. van Griensven F, de Lind van Wijngaarden JW, Baral SD, Grulich AE. The global epidemic of HIV infection among men who have sex with men. Curr Opin HIV AIDS 2009;4(4):300-307. [ Links ]
14. Hughes G, Simms I, Leong G. Data from UK genitourinary medicine clinics, 2006: a mixed picture. Sex Transm Infect 2007;83(6):433-435. [ Links ]
15. Savage E, Hughes G, Ison C, Lowndes CM. Syphilis and gonorrhoea in men who have sex with men: a European overview. Eurosurveillance 2009;14(47):1-8. [ Links ]
16. Grant R, Lama JR, Anderson PL, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med 2010;363(27):2587-2599. [ Links ]
17. Karim QA, Karim SSA, Frohlich JA, et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV Infection in women. Science 2010;329(5996):1168-1174. [ Links ]
18. Siegfried N, Muller M, Deeks JJ, Volmink J. Male circumcision for prevention of heterosexual acquisition of HIV in men. Cochrane Database Systematic Reveiws 2009;15(2). [ Links ]
19. Lane T, Raymond HF, Dladla S, et al. Lower risk of HIV infection among circumcised MSM: Results from the Soweto Men's Study. Presented at the 5th International Aids Society Conference on HIV Pathogenesis, Treatment and Prevention, Cape Town, 19-22 July 2010. [ Links ]
20. Millett GA, Flores SA, Marks G, Reed JB, Herbst JH. Circumcision status and risk of HIV and sexually transmitted infections among men who have sex with men: a meta-analysis. JAMA 2008;301(11):11261129. [ Links ]
21. Templeton DJ, Millett GA, Grulich AE. Male circumcision to reduce the risk of HIV and sexually transmitted infections among men who have sex with men. Curr Opin Infect Dis 2010;23(1):45-52. [ Links ]
22. NIH. Treating HIV-infected people with antiretrovirals protects partners from infection. Findings result from NIH-funded international study. Bethesda, Md: NIH, 2011 News Release. http://www.niaid.nih.gov/news/newsreleases/2011/pages/hptn052.aspx (accessed 1 July 2011). [ Links ]
Declaration of conflict of interest. The authors have no conflicts of interest to declare.
Support. The authors are supported in part by PEPFAR through USAID under the terms of Award No. 674-A-00-08-00009-00. The opinions expressed herein are those of the authors and do not necessarily reflect the views of USAID.
Dr Kevin Rebe is the medical director of Health4Men, a project of the Anova Health Institute, and an honorary consultant in the departments of Medicine and Infectious Diseases at Groote Schuur Hospital, Cape Town. An infectious diseases specialist with a special interest in providing health care services to men who have sex with men (MSM), he currently heads the Ivan Toms Centre for Men's Health, which provides primary-level sexual health prevention and treatment services to MSM.
Helen Struthers has master's degrees in Applied Mathematics and Business Science. She has been involved in HIV and AIDS research and implementation of HIV services for over 10 years. Helen has a keen interest in the social aspects of the epidemic, particularly the intersection of men and the HIV epidemic, including MSM.
Glenn de Swardt is the project director of Health4Men, a project of the Anova Health Institute. His background is in psychiatric social work, and he has spent 15 years working in the field of MSM mental and sexual health.
James McIntyre is the Executive Director of the Anova Health Institute, International Vice-Chair of the US National Institutes for Health-funded International Maternal Paediatric and Adolescent AIDS Clinical Trials Network (IMPAACT), and an Honorary Professor in the School of Public Health and Family Medicine at the University of Cape Town. He is an internationally recognised expert on mother-to-child transmission of HIV and works across a range of HIV prevention and treatment projects, including innovative services for MSM.
Corresponding author: K Rebe (firstname.lastname@example.org)